News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rockwell Medical (RMTI) Announces Triferic™ Iron Replacement Clinical Data Selected For Three Abstract Presentations At National Kidney Foundation Spring Clinical Meetings April 22-26, 2014 In Las Vegas, NV


4/14/2014 9:16:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WIXOM, Mich., April 14, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that three individual abstracts for Trifericâ„¢ have been selected by the National Kidney Foundation for presentation at their Spring Clinical Meetings, April 22-26, 2014 in Las Vegas, Nevada. Trifericâ„¢ is the Company's late-stage investigational iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES